NCT00703482View on ClinicalTrials.gov

A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions
Patients With Type 2 Diabetes
Interventions
DRUG

Fenofibrate/CoQ10

Fenofibrate pbo/CoQ10 placebo

DRUG

Fenofibrate/CoQ10

Fenofibrate pbo/CoQ10 200 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 160mg/CoQ10 placebo

DRUG

Fenofibrate/CoQ10

Fenofibrate 80/CoQ10 100 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 160mg/CoQ10 100 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 80 /CoQ10 200 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 160mg/CoQ10 200 mg

Trial Locations (3)

Unknown

Site 002, Fremantle

Site 003, Nedlands

Site 001, Perth

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00703482 - A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter